Innovax-ND-IBD

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
04-11-2021
Karakteristik produk Karakteristik produk (SPC)
04-11-2021

Bahan aktif:

Cell-associated live recombinant turkey herpesvirus (strain HVP360), expressing the fusion protein of ND virus and the VP2 protein of IBD virus

Tersedia dari:

Intervet International B.V.

Kode ATC:

QI01AD16

INN (Nama Internasional):

Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)

Kelompok Terapi:

Chicken; Embryonated chicken eggs

Area terapi:

avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus

Indikasi Terapi:

For active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by Newcastle disease (ND) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (IBD) virus,to reduce mortality, clinical signs and lesions caused by Marek’s disease (MD) virus.

Ringkasan produk:

Revision: 5

Status otorisasi:

Authorised

Tanggal Otorisasi:

2017-08-22

Selebaran informasi

                                14
B. PACKAGE LEAFLET
15
PACKAGE LEAFLET:
INNOVAX-ND-IBD CONCENTRATE AND SOLVENT FOR SUSPENSION FOR INJECTION
FOR CHICKENS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
THE NETHERLANDS
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Innovax-ND-IBD concentrate and solvent for suspension for injection
for chickens
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of the reconstituted vaccine (0.2 ml for subcutaneous use or
0.05 ml for
_in ovo_
use)
contains:
Cell-associated live recombinant turkey herpesvirus (strain HVP360),
expressing the fusion protein of
Newcastle disease virus and the VP2 protein of infectious bursal
disease virus:
10
3.3
– 10
4.6
PFU
1
.
1
PFU – plaque forming units.
Concentrate and solvent for suspension for injection.
Cell concentrate: off-red to red cell concentrate.
Solvent: clear, red solution.
4.
INDICATION(S)
For active immunisation of one-day-old chicks or 18–19 day-old
embryonated chicken eggs:
-
to reduce mortality and clinical signs caused by Newcastle disease
(ND) virus,
-
to prevent mortality and to reduce clinical signs and lesions caused
by infectious bursal disease
(IBD) virus,
-
to reduce mortality, clinical signs and lesions caused by Marek’s
disease (MD) virus.
Onset of immunity:
ND: 4 weeks of age,
IBD: 3 weeks of age,
MD: 9 days.
Duration of immunity:
ND: 60 weeks,
IBD: 60 weeks,
MD: entire risk period.
5.
CONTRAINDICATIONS
None.
16
6.
ADVERSE REACTIONS
None known.
If you notice any side effects, even those not already listed in this
package leaflet or you think that the
medicine has not worked, please inform your veterinary surgeon.
7.
TARGET SPECIES
Chickens and embryonated chicken eggs.
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
After dilution, administer 1 dose of 0.2 ml va
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Innovax-ND-IBD concentrate and solvent for suspension for injection
for chickens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of the reconstituted vaccine (0.2 ml for subcutaneous use or
0.05 ml for
_in ovo_
use)
contains:
ACTIVE SUBSTANCE:
Cell-associated live recombinant turkey herpesvirus (strain HVP360),
expressing the fusion protein of
Newcastle disease virus and the VP2 protein of infectious bursal
disease virus:
10
3.3
– 10
4.6
PFU
1
.
1
PFU – plaque forming units.
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate and solvent for suspension for injection.
Cell concentrate: off-red to red cell concentrate.
Solvent: clear, red solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens and embryonated chicken eggs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of one-day-old chicks or 18–19 day-old
embryonated chicken eggs:
-
to reduce mortality and clinical signs caused by Newcastle disease
(ND) virus,
-
to prevent mortality and to reduce clinical signs and lesions caused
by infectious bursal disease
(IBD) virus,
-
to reduce mortality, clinical signs and lesions caused by Marek’s
disease (MD) virus.
Onset of immunity:
ND: 4 weeks of age,
IBD: 3 weeks of age,
MD: 9 days.
Duration of immunity:
ND: 60 weeks,
IBD: 60 weeks,
MD: entire risk period.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As this is a live vaccine, the vaccine strain is excreted from
vaccinated birds and may spread to
turkeys. Safety trials have shown that the strain is safe for turkeys.
However, precautionary measures
have to be followed in order to avoid direct or indirect contact
between vaccinated chickens and
turkeys.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 04-11-2021
Karakteristik produk Karakteristik produk Bulgar 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 09-03-2021
Selebaran informasi Selebaran informasi Spanyol 04-11-2021
Karakteristik produk Karakteristik produk Spanyol 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 09-03-2021
Selebaran informasi Selebaran informasi Cheska 04-11-2021
Karakteristik produk Karakteristik produk Cheska 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 09-03-2021
Selebaran informasi Selebaran informasi Dansk 04-11-2021
Karakteristik produk Karakteristik produk Dansk 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 09-03-2021
Selebaran informasi Selebaran informasi Jerman 04-11-2021
Karakteristik produk Karakteristik produk Jerman 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 09-03-2021
Selebaran informasi Selebaran informasi Esti 04-11-2021
Karakteristik produk Karakteristik produk Esti 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 09-03-2021
Selebaran informasi Selebaran informasi Yunani 04-11-2021
Karakteristik produk Karakteristik produk Yunani 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 09-03-2021
Selebaran informasi Selebaran informasi Prancis 04-11-2021
Karakteristik produk Karakteristik produk Prancis 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 09-03-2021
Selebaran informasi Selebaran informasi Italia 04-11-2021
Karakteristik produk Karakteristik produk Italia 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 09-03-2021
Selebaran informasi Selebaran informasi Latvi 04-11-2021
Karakteristik produk Karakteristik produk Latvi 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 09-03-2021
Selebaran informasi Selebaran informasi Lituavi 04-11-2021
Karakteristik produk Karakteristik produk Lituavi 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 09-03-2021
Selebaran informasi Selebaran informasi Hungaria 04-11-2021
Karakteristik produk Karakteristik produk Hungaria 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 09-03-2021
Selebaran informasi Selebaran informasi Malta 04-11-2021
Karakteristik produk Karakteristik produk Malta 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 09-03-2021
Selebaran informasi Selebaran informasi Belanda 04-11-2021
Karakteristik produk Karakteristik produk Belanda 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 09-03-2021
Selebaran informasi Selebaran informasi Polski 04-11-2021
Karakteristik produk Karakteristik produk Polski 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 09-03-2021
Selebaran informasi Selebaran informasi Portugis 04-11-2021
Karakteristik produk Karakteristik produk Portugis 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 09-03-2021
Selebaran informasi Selebaran informasi Rumania 04-11-2021
Karakteristik produk Karakteristik produk Rumania 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 09-03-2021
Selebaran informasi Selebaran informasi Slovak 04-11-2021
Karakteristik produk Karakteristik produk Slovak 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 09-03-2021
Selebaran informasi Selebaran informasi Sloven 04-11-2021
Karakteristik produk Karakteristik produk Sloven 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 09-03-2021
Selebaran informasi Selebaran informasi Suomi 04-11-2021
Karakteristik produk Karakteristik produk Suomi 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 09-03-2021
Selebaran informasi Selebaran informasi Swedia 04-11-2021
Karakteristik produk Karakteristik produk Swedia 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 09-03-2021
Selebaran informasi Selebaran informasi Norwegia 04-11-2021
Karakteristik produk Karakteristik produk Norwegia 04-11-2021
Selebaran informasi Selebaran informasi Islandia 04-11-2021
Karakteristik produk Karakteristik produk Islandia 04-11-2021
Selebaran informasi Selebaran informasi Kroasia 04-11-2021
Karakteristik produk Karakteristik produk Kroasia 04-11-2021
Laporan Penilaian publik Laporan Penilaian publik Kroasia 09-03-2021

Lihat riwayat dokumen